ANTHONY HAYDEN LIVE 🎙

Thanks so much to Jarod and his boss/funder James Fickel - as well as Michael Greve, who funded this work both at Revel (through Kizoo) and at SENS before Revel was created. Without their visionary contributions to this and other early-stage work, we'd be far further from LEV.

it's insane to me that this isn't all over mainstream media right now. for the first time in human history, a drug built to reverse aging was just put into a living person a company called Life Biosciences dosed the first patient in their trial for something called ER-100 it comes from a Harvard geneticist named David Sinclair his theory is that aging comes from your cells losing track of how to read their own DNA think of it like a computer. the hardware is fine, but the software slowly gets corrupted over the years, so the machine runs slower and slower until it stops the instructions for a young, healthy cell are all still in there. your cells just lost access to them over time so this drug does one thing: it reboots the cell back to the version of itself that knew how to run properly they pull it off with three proteins that reset a cell to a younger state and they proved it works before ever touching a human first they restored vision in old mice. then they restored vision in monkeys with optic nerve damage, with no tumors and no signs of harm so now they're testing it on people going blind from glaucoma and a nerve condition called NAION they started with the eye on purpose. it's the cleanest place to test the idea, because they can inject it into one eye without it reaching the rest of the body, the cells there don't heal on their own so any improvement clearly came from the drug, and they can measure vision right down to the letters on a chart the reset happens at the level of the cell, so in theory the same approach could one day rejuvenate the liver, the kidneys, even the brain it won't be automatic though. every organ needs its own way of getting the drug into the right cells, plus its own round of safety testing. so it doesn't suddenly work everywhere the moment it works in the eye but the eye answers the one question nobody could answer before: whether you can safely turn back the age of living cells inside a person if the answer is yes, reaching the rest of the body comes down to delivery, one organ at a time. that part is hard, but it's the kind of hard you can engineer your way through to be clear, this is an early safety trial. 18 people, 5 year follow up. so nobody is gonna cure aging by next year but if it works, we'll look back at this week as the moment the clock started running backwards for the first time

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…